Antihypertensive drug/en: Difference between revisions

(One intermediate revision by the same user not shown)

Line 1:

Line 90:

Line 92:

* [[valsartan]]

* [[Fimasartan]]

In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.~~{{citation needed|date=July 2019}}~~

In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.

In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with [[amlodipine]].

Line 140:

Line 142:

==Vasodilators==

[[Vasodilator]]s act directly on the [[smooth muscle]] of arteries to relax their walls so blood can move more easily through them; they are only used in [[hypertensive emergency|hypertensive emergencies]] or when other drugs have failed, and even so are rarely given alone.~~{{cn|date=March 2023}}~~

[[Vasodilator]]s act directly on the [[smooth muscle]] of arteries to relax their walls so blood can move more easily through them; they are only used in [[hypertensive emergency|hypertensive emergencies]] or when other drugs have failed, and even so are rarely given alone.

[[Sodium nitroprusside]], a very potent, short-acting vasodilator, is most commonly used for the quick, temporary reduction of blood pressure in emergencies (such as [[malignant hypertension]] or [[aortic dissection]]).[[Hydralazine]] and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies. They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in [[gestational hypertension]].

Line 148:

Line 150:

==Aldosterone receptor antagonist==

[[Aldosterone]] receptor antagonists:~~{{cn|date=March 2023}}~~

[[Aldosterone]] receptor antagonists:

* [[eplerenone]]

* [[spironolactone]]

@@ Line 1: / Line 1: @@
+{{Drug List/ja}}
+{{PathNav|Medication/ja}}
 <languages />
 {{Short description|all drugs for hypertension's treatment}}
@@ Line 90: / Line 92: @@
 * [[valsartan]]
 * [[Fimasartan]]
-In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.{{citation needed|date=July 2019}}
+In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.
 In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with [[amlodipine]].
@@ Line 140: / Line 142: @@
 ==Vasodilators==
-[[Vasodilator]]s act directly on the [[smooth muscle]] of arteries to relax their walls so blood can move more easily through them; they are only used in [[hypertensive emergency|hypertensive emergencies]] or when other drugs have failed, and even so are rarely given alone.{{cn|date=March 2023}}
+[[Vasodilator]]s act directly on the [[smooth muscle]] of arteries to relax their walls so blood can move more easily through them; they are only used in [[hypertensive emergency|hypertensive emergencies]] or when other drugs have failed, and even so are rarely given alone.
 [[Sodium nitroprusside]], a very potent, short-acting vasodilator, is most commonly used for the quick, temporary reduction of blood pressure in emergencies (such as [[malignant hypertension]] or [[aortic dissection]]).[[Hydralazine]] and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies. They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in [[gestational hypertension]].
@@ Line 148: / Line 150: @@
 ==Aldosterone receptor antagonist==
-[[Aldosterone]] receptor antagonists:{{cn|date=March 2023}}
+[[Aldosterone]] receptor antagonists:
 * [[eplerenone]]
 * [[spironolactone]]